Pupillary dilation a must for OCT

Article

High quality optical coherence tomography (OCT) images cannot be obtained in a large percentage of glaucoma patients without pupillary dilation.

High quality optical coherence tomography (OCT) images cannot be obtained in a large percentage of glaucoma patients without pupillary dilation, according to a report published in the December issue of the British Journal of Ophthalmology.

Michael Smith from Torbay Hospital, Devon, UK and colleagues from the Peninsula Medical School and the University of Plymouth, Devon conducted an observational study of 38 patients attending a glaucoma clinic in order to examine the effect of pupillary dilation on the reliability of retinal nerve fibre layer (RNFL) and optic nerve head (ONH) assessments using the Stratus OCT (Carl Zeiss). The "fast optic disc" and "fast RNFL thickness" programmes on the Stratus were used to measure the RNFL thickness and ONH cup-to-disc ratio (CDR). Two scans were performed prior to dilation and two following dilation with tropicamide 1% drops.

In nine patients (23.7%) no images were obtained prior to dilation however, following dilation, examination was possible in all patients. Inability to obtain an undilated scan was associated with smaller pupil size and increasing cataract. The scan quality, as determined by the signal strength score, was higher when pupils were dilated for both RNFL thickness (p=0.011) and ONH CDR (p=0.007).

The authors of this study believe that attaining high quality OCT images is not possible without pupillary dilation, in about 25% of patients.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.